Determinants of spironolactone binding specificity in the mineralocorticoid receptor

Journal of Molecular Endocrinology

Volumn 31, Issue 3, 2003, Pages 573-582

  Rogerson, Fraser M ^b   Yao, Y Z ^b   Smith, B J ^a   Dimopoulos, N ^b   Fuller, P J ^b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; AMINO ACID; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; HISTONE H3; MINERALOCORTICOID RECEPTOR; PROGESTERONE RECEPTOR; SPIRONOLACTONE;

ANIMAL CELL; ARTICLE; CHIMERA; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; DRUG STRUCTURE; EXPERIMENTAL MODEL; HYDROPHOBICITY; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; STRUCTURE ANALYSIS;

ALDOSTERONE; BINDING, COMPETITIVE; CLONING, MOLECULAR; DEXAMETHASONE; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, GLUCOCORTICOID; RECEPTORS, MINERALOCORTICOID; RECEPTORS, PROGESTERONE; RECOMBINANT FUSION PROTEINS; SPIRONOLACTONE;

EID: 0347989294     PISSN: 09525041     EISSN: None     Source Type: Journal    
DOI: 10.1677/jme.0.0310573     Document Type: Article

References (33)

1. Arriza JL 1991 Aldosterone action: perspectives from the cloning of the mineralocorticoid receptor. In Aldosterone: Fundamental Aspects, pp 13 21. Eds JP Bonvalet, N Farman & M Lombès. Paris: Colloque INSERM/John Libbey Eurotext.
2. Arriza JL,Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE & Evans RM 1987 Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 237 268-275.
3. Auzuo G, Fagart J, Souque A, Hellal-Lévy C, Wurtz J-M, Moras D & Rafestin-Oblin M-E 2000 A single amino acids mutation of Ala-773 in the mineralocorticoid receptor confers agonist properties to 11β-substituted spirolactones. Molecular Pharmacology 58 684-691.
4. Bledsoe RK, Montana VG, Stanley TB, Delves CJ, Apolito CJ, McKee DD, Consler TG, Parks DJ, Stewart EL, Willson TM, Lambert MH, Moore JT, Pearce KH & Xu HE 2002 Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 110 93-105.
5. Corvol P, Michaud A, Menard J, Freifeld M & Mahoudeau J 1975 Antiandrogenic effect of spirolactones: mechanism of action. Endocrinology 97 52-58.
6. Corvol P, Claire M, Oblin ME, Geering K & Rossier B 1981 Mechanism of the antimineralocorticoid effects of spirolactones. Kidney International 20 1-6.
7. Couette B, Lombès M, Baulieu E-E & Rafestin-Oblin M-E 1992a Aldosterone antagonists destabilize the mineralocorticoid receptor. Biochemical Journal 282 697-702.
8. Couette B, Marsaud V, Baulieu E-E, Richard-Foy H & Rafestin-Oblin M-E 1992b Spironolactone, an aldosterone antagonist, acts as an antiglucocorticoid on the mouse mammary tumor virus promoter. Endocrinology 130 430-436.
9. Doggrell SA & Brown L 2001 The spironolactone renaissance. Expert Opinion on Investigational Drugs 10 943-954.
10. Eisen LP & Harmon JM 1986 Activation of the rat kidney mineralocorticoid receptor. Endocrinology 119 1419-1426.
11. Fagart J. Wurtz J-M, Souque A, Hellal-Levy C, Moras D & Rafestin-Oblin M-E 1998 Antagonism in the human mineralocorticoid receptor. EMB0 Journal 17 3317-3325.
12. Funder JW, Pearce PT, Smith R & Smith AI 1988 Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242 583-585.
13. Fuse H, Kitagawa H & Kato S 2000 Characterization of transactivational property and coactivator mediation of rat mineralocorticoid receptor activation function-1 (AF-1). Molecular Endocrinology 14 889-899.
14. Geller DS, Farhi A, Pinkerton N, Fradley M, Moritz M, Spitzer A, Meinke G, Tsai FTF, Sigler PB & Lifton RP 2000 Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 289 119-123.
15. Giannoukos G, Silverstein AM, Pratt WB & Simons SS Jr 1999 The seven amino acids (547-553) of rat glucocorticoid receptor required for steroid and hsp90 binding contain a functionally independent LXXLL motif that is critical for steroid binding. Journal of Biological Chemistry 274 36527-36536.
16. Govindan MV & Warriar N 1998 Reconstitution of the N-terminal transcription activation function of human mineralocorticoid receptor in a defective human glucocorticoid receptor. Journal of Biological Chemistry 273 24439-24447.
17. Hong H, Kohli K, Garabedian MJ & Stallcup MR 1997 GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid and vitamin D receptors. Molecular and Cellular Biology 17 2735-2744.
18. Keightley M-C, Curtis AJ, Chu S & Fuller PJ 1998 Structural basis of cortisol resistance in the guinea pig glucocorticoid receptor. Endocrinology 139 2479-2485.
19. Knutti D, Kaul A & Kralli A 2000 A tissue-specific coactivator of steroid receptor, identified in a functional yeast screen. Molecular and Cellular Biology 20 2411-2422.
20. Kraulis PJ 1991 MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. Applied Crystalography 24 946-950.
21. Lind U, Greenidge P, Gillner M, Koehler KF, Wright A & Carlstedt-Duke J 2000 Functional probing of the human glucocorticoid receptor steroid-interacting surface by site-directed mutagenesis: Gln-642 plays an important role in steroid recognition and binding. Journal of Biological Chemistry 275 19041-19049.
22. Liu W, Wang J, Yu G & Pearce D 1996 Steroid receptor transcriptional synergy is potentiated by disruption of the DNA-binding domain dimer interface. Molecular Endocrinology 10 1399-1406.
23. Merrit EA & Bacon DJ 1997 Raster3D: photorealistic molecular graphics. Methods in Enzymology 277 505-524.
24. Nemoto T, Ohara-Nemoto Y, Sato N & Ota M 1993 Dual role of 90-kDa treat shock protein in the function of the mineralocorticoid receptor. Journal of Biochemistry 113 769-775.
25. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J & Wittes J 1999 The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New England Journal of Medicine 341 709-717.
26. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J & Gatlin M 2003 Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New England Journal of Medicine 348 1309-1321.
27. Robin-Jagerschmidt C, Wurtz J-M, Guillot B, Gofflo D, Benhamou B, Vergezac A, Ossart C, Moras D & Philibert D 2000 Residues in the ligand binding domain that confer progestin or glucocorticoid specificity and modulate the receptor transactivation capacity. Molecular Endocrinology 14 1028-1037.
28. Rogerson FM & Fuller PJ 2000 Mineralocorticoid action. Steroids 65 61-73.
29. Rogerson FM, Dimopoulos N, Sluka P, Chu S, Curtis AJ & Fuller PJ 1999 Structural determinants of aldosterone binding selectivity in the mineralocorticoid receptor. Journal of Biological Chemistry 274 36305-36311.
30. Roux S, Térouanne B, Balaguer P, Jausons-Loffreda N, Pons M, Chambon P, Gronemeyer H & Nicolas J-C 1996 Mutation of isoleucine 747 by a threonine alters the ligand responsiveness of the human glucocorticoid receptor. Molecular Endocrinology 10 1214-1226.
31. Rupprecht R, Arriza JL, Spengler D, Reul JMHM, Evans RM, Holsboer F & Damm K 1993a Transactivation and synergistic properties of the mineralocorticoid receptor: relationship to the glucocorticoid receptor. Molecular Endocrinology 7 597-603.
32. Rupprecht R, Reul JMHM, van Steensel B, Spengler D, Söder M, Berning B, Holsboer F & Damm K 1993b Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. European Journal of Pharmacology 247 145-154.
33. Williams SP & Sigler PB 1998 Atomic structure of progesterone complexed with its receptor. Nature 393 392-396.